193 related articles for article (PubMed ID: 34919890)
1. Simultaneous nanocarrier-mediated delivery of siRNAs and chemotherapeutic agents in cancer therapy and diagnosis: Recent advances.
Bidar N; Darroudi M; Ebrahimzadeh A; Safdari M; de la Guardia M; Baradaran B; Goodarzi V; Oroojalian F; Mokhtarzadeh A
Eur J Pharmacol; 2022 Jan; 915():174639. PubMed ID: 34919890
[TBL] [Abstract][Full Text] [Related]
2. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.
Gandhi NS; Tekade RK; Chougule MB
J Control Release; 2014 Nov; 194():238-56. PubMed ID: 25204288
[TBL] [Abstract][Full Text] [Related]
3. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
4. Delivery of small interfering RNAs by nanovesicles for cancer therapy.
Pengnam S; Plianwong S; Yingyongnarongkul BE; Patrojanasophon P; Opanasopit P
Drug Metab Pharmacokinet; 2022 Feb; 42():100425. PubMed ID: 34954489
[TBL] [Abstract][Full Text] [Related]
5. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
6. Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus.
Sohrab SS; El-Kafrawy SA; Mirza Z; Kamal MA; Azhar EI
Curr Pharm Des; 2018; 24(1):62-77. PubMed ID: 29119921
[TBL] [Abstract][Full Text] [Related]
7. Nanovehicle-based Small Interfering RNA (siRNA) Delivery for Therapeutic Purposes: A New Molecular Approach in Pharmacogenomics.
Akhtari J; Tafazoli A; Mehrad-Majd H; Mahrooz A
Curr Clin Pharmacol; 2018; 13(3):173-182. PubMed ID: 29992895
[TBL] [Abstract][Full Text] [Related]
8. Recent Advancements in the Design of Nanodelivery Systems of siRNA for Cancer Therapy.
Yadav DN; Ali MS; Thanekar AM; Pogu SV; Rengan AK
Mol Pharm; 2022 Dec; 19(12):4506-4526. PubMed ID: 36409653
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
10. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
[TBL] [Abstract][Full Text] [Related]
11. The Daniel K. Inouye College of Pharmacy Scripts: Targeted Nanocarrier Based Systems for the Treatment of Lung Cancer.
Youngren-Ortiz SR; Chougule MB
Hawaii J Med Public Health; 2017 Nov; 76(11):318-325. PubMed ID: 29164017
[TBL] [Abstract][Full Text] [Related]
12. Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo.
Aigner A
J Biomed Biotechnol; 2006; 2006(4):71659. PubMed ID: 17057369
[TBL] [Abstract][Full Text] [Related]
13. Confocal microscopy for the analysis of siRNA delivery by polymeric nanoparticles.
Portis AM; Carballo G; Baker GL; Chan C; Walton SP
Microsc Res Tech; 2010 Sep; 73(9):878-85. PubMed ID: 20803695
[TBL] [Abstract][Full Text] [Related]
14. Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics.
Cuciniello R; Filosa S; Crispi S
J Exp Clin Cancer Res; 2021 Dec; 40(1):383. PubMed ID: 34863235
[TBL] [Abstract][Full Text] [Related]
15. Photoinduced RNA interference.
Matsushita-Ishiodori Y; Ohtsuki T
Acc Chem Res; 2012 Jul; 45(7):1039-47. PubMed ID: 22360585
[TBL] [Abstract][Full Text] [Related]
16. Targeting Cell Adhesion Molecules via Carbonate Apatite-Mediated Delivery of Specific siRNAs to Breast Cancer Cells In Vitro and In Vivo.
Ashaie MA; Islam RA; Kamaruzman NI; Ibnat N; Tha KK; Chowdhury EH
Pharmaceutics; 2019 Jul; 11(7):. PubMed ID: 31269666
[TBL] [Abstract][Full Text] [Related]
17. Current Development of siRNA Bioconjugates: From Research to the Clinic.
Chernikov IV; Vlassov VV; Chernolovskaya EL
Front Pharmacol; 2019; 10():444. PubMed ID: 31105570
[TBL] [Abstract][Full Text] [Related]
18. Enabling Combinatorial siRNA Delivery against Apoptosis-Related Proteins with Linoleic Acid and α-Linoleic Acid Substituted Low Molecular Weight Polyethylenimines.
Plianwong S; Thapa B; Kc RB; Kucharski C; Rojanarata T; Uludağ H
Pharm Res; 2020 Feb; 37(3):46. PubMed ID: 32016611
[TBL] [Abstract][Full Text] [Related]
19. Multifunctional nanoparticles co-delivering EZH2 siRNA and etoposide for synergistic therapy of orthotopic non-small-cell lung tumor.
Yuan ZQ; Chen WL; You BG; Liu Y; Yang SD; Li JZ; Zhu WJ; Zhou XF; Liu C; Zhang XN
J Control Release; 2017 Dec; 268():198-211. PubMed ID: 29061511
[TBL] [Abstract][Full Text] [Related]
20. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
Aigner A
J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
